About Linagliptin API
Therapeutic CategoryAnti-diabético
CAS Number
668270-12-0
API Technology
Synthetic
Dose Form
Oral Solid/Tablets
Dr Reddy's Development Status
Available
Available Regulatory Filing
USDMF, Brazil DMF, EUDMF, Canada DMF, Korea DMF
Mechanism of Action
Linagliptin is an inhibitor of DPP-4, an enzyme that degrades the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Thus, linagliptin increases the concentrations of active incretin hormones, stimulating the release of insulin in a glucose-dependent manner and decreasing the levels of glucagon in the circulation. Both incretin hormones are involved in the physiological regulation of glucose homeostasis. Incretin hormones are secreted at a low basal level throughout the day and levels rise immediately after meal intake. GLP-1 and GIP increase insulin biosynthesis and secretion from pancreatic beta-cells in the presence of normal and elevated blood glucose levels. Furthermore, GLP-1 also reduces glucagon secretion from pancreatic alpha-cells, resulting in a reduction in hepatic glucose output.
Indication
TRADJENTA is a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Related APIs
Glimepirida
Anti-diabético
Linagliptina
Anti-diabético
Liraglutida
Anti-diabético
Pioglitazona Clorhidrato
Anti-diabético
Clorhidrato De Sitagliptina
Anti-diabético
Dapagliflozina (amorfa)
Anti-diabético
Request for Quotation
Get in touch with us by filling out the form below. Our team will reach out to you shortly!
Related Resources
Tech Sheet on Linagliptin
Linagliptin is an inhibitor of dipeptidyl peptidase-4 (DPP-4), an enzyme that degrades the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Thus, linagliptin increases the concentrations of active incretin hormones, stimulating the release of insulin in a glucose-dependent manner and decreasing the levels of glucagon in circulation. Both incretin hormones are involved in the physiological regulation of glucose homeostasis.
We are among the earliest generic API manufacturers globally to file the USDMF for Linagliptin API. The DMF for Korea is also filled. We offer country-specific regulatory filings for global market expansion, so we are diversifying our filing to all the major regulated markets.
Our API offerings:
- We offer a mixture of crystalline Form A and Form B - a prior art form
- A process which is improved and disclosed in the product patent and designed around the innovator's process IP.
- Quality by design (QbD) based API development for a consistent quality profile
Our process has been designed to address customized PSD requirements through size reduction and crystallization techniques to consistently meet the most desired PSDs at a commercial scale.
To know more about our API offerings, please read the Tech sheet on Linagliptin by filling the contact form below.
Descargo de responsabilidad
Ninguna información en este sitio web, incluyendo cualquier referencia a cualquier producto o servicio, constituye una oferta de venta ni se interpretará como tal. Los productos protegidos por patentes válidas no se ofrecen ni suministran para uso comercial. Sin embargo, en ciertos casos, a discreción exclusiva de Dr. Reddy's y sujeto a los requisitos legales locales, las cantidades de investigación de dichos productos pueden ofrecerse para fines de presentaciones regulatorias según la Sección 107A de la Ley de Patentes de la India (exención de Bolar), donde existan dichas exenciones regulatorias. Los compradores deben realizar su propia evaluación del producto o servicio, incluyendo el escenario de patentes en sus respectivos mercados, y serán responsables de todas las responsabilidades relacionadas con las patentes. Dr. Reddy's renuncia a todas las garantías, expresas o implícitas, incluyendo, entre otras, las garantías de comerciabilidad, idoneidad para un propósito particular y no infracción.